ASND0029 "IL Believe": A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in

HOLIDAY CLOSURES

SIU Medicine clinics will be closed Dec. 24–25, Dec. 31, and Jan. 1. Most clinics will remain open Dec. 26, 29, and 30. SIU Medicine Express Care | Springfield will be open on Christmas Eve and New Year’s Eve from 8 a.m. to 5 p.m.

This study is investigating experimental drugs TransCon IL-2 β/γ and TransCon TLR7/8 for the treatment of advanced/metastatic solid tumors (melanoma, breast cancer, cervical cancer, ovarian cancer) in adults.

Research

Patient

Simmons Cancer Institute

Active, recruiting

217-545-1946

Related Profiles

Krishna Rao

sciresearchbc@siumed.edu

Kathy Robinson

https://clinicaltrials.gov/study/NCT05081609

Cancer Care

Internal Medicine